- Conditions
- Metabolic Syndrome X
- Interventions
- Astaxanthin, Placebo
- Dietary Supplement · Other
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- San Diego, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 104
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diabetes, Metabolic Syndrome x
- Interventions
- borage/echium oil combination, fish oil, corn oil
- Drug · Dietary Supplement
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Obesity, Metabolic Syndrome X
- Interventions
- Metformin, Orlistat, Topiramate, Placebo
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Metabolic Syndrome X
- Interventions
- Aripiprazole
- Drug
- Lead sponsor
- New Mexico VA Healthcare System
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Post-menopause
- Interventions
- Study Procedures
- Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 45 Years and older · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia
- Conditions
- Cardiovascular Diseases, Heart Diseases, Metabolic Syndrome X, Obesity
- Interventions
- Exercise, Weight Loss, Health Education Control
- Behavioral
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 60 Years to 79 Years
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 3
- States / cities
- Greensboro, North Carolina • Lexington, North Carolina • Winston-Salem, North Carolina
- Conditions
- Cardiovascular Diseases, Heart Diseases, Obesity, Metabolic Syndrome X
- Interventions
- Not listed
- Lead sponsor
- Emory University
- Other
- Eligibility
- 30 Years to 78 Years
- Enrollment
- 4,024 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2009
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Metabolic Syndrome X
- Interventions
- Omega-3 fatty acids
- Dietary Supplement
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Metabolic Syndrome X, Prediabetic State, Insulin Resistance, Obesity, Metabolic Diseases
- Interventions
- Chromium picolinate
- Drug
- Lead sponsor
- National Center for Complementary and Integrative Health (NCCIH)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Spinal Muscular Atrophy, Fragile X Syndrome, Fragile X - Premutation, Duchenne Muscular Dystrophy, Hyperinsulinemic Hypoglycemia, Familial 1, Diabetes Mellitus, Adrenoleukodystrophy, Neonatal, Medium-chain Acyl-CoA Dehydrogenase Deficiency, Very Long Chain Acyl Coa Dehydrogenase Deficiency, Beta-ketothiolase Deficiency, Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency, Primary Hyperoxaluria Type 1, Congenital Bile Acid Synthesis Defect Type 2, Pyridoxine-Dependent Epilepsy, Hereditary Fructose Intolerance, Hypophosphatasia, Hyperargininemia, Mucopolysaccharidosis Type 6, Argininosuccinic Aciduria, Citrullinemia, Type I, Wilson Disease, Maple Syrup Urine Disease, Type 1A, Maple Syrup Urine Disease, Type 1B, Biotinidase Deficiency, Neonatal Severe Primary Hyperparathyroidism, Intrinsic Factor Deficiency, Usher Syndrome Type 1D/F Digenic (Diagnosis), Cystic Fibrosis, Stickler Syndrome Type 2, Stickler Syndrome Type 1, Alport Syndrome, Autosomal Recessive, Alport Syndrome, X-Linked, Carbamoyl Phosphate Synthetase I Deficiency Disease, Carnitine Palmitoyl Transferase 1A Deficiency, Carnitine Palmitoyltransferase II Deficiency, Cystinosis, Chronic Granulomatous Disease, Cerebrotendinous Xanthomatoses, Maple Syrup Urine Disease, Type 2, Severe Combined Immunodeficiency Due to DCLRE1C Deficiency, Thyroid Dyshormonogenesis 6, Thyroid Dyshormonogenesis 5, Supravalvar Aortic Stenosis, Factor X Deficiency, Hemophilia A, Hemophilia B, Tyrosinemia, Type I, Fructose 1,6 Bisphosphatase Deficiency, Glycogen Storage Disease Type I, G6PD Deficiency, Glycogen Storage Disease II, Galactokinase Deficiency, Mucopolysaccharidosis Type IV A, Galactosemias, Guanidinoacetate Methyltransferase Deficiency, Agat Deficiency, Glutaryl-CoA Dehydrogenase Deficiency, Gtp Cyclohydrolase I Deficiency, Hyperinsulinism-Hyperammonemia Syndrome, Primary Hyperoxaluria Type 2, 3-Hydroxyacyl-CoA Dehydrogenase Deficiency, Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency, Mitochondrial Trifunctional Protein Deficiency, Sickle Cell Disease, Beta-Thalassemia, Holocarboxylase Synthetase Deficiency, 3-Hydroxy-3-Methylglutaric Aciduria, Primary Hyperoxaluria Type 3, Hermansky-Pudlak Syndrome 1, Hermansky-Pudlak Syndrome 4, Apparent Mineralocorticoid Excess, HSDB, CBAS1, Mucopolysaccharidosis Type 2, Mucopolysaccharidosis Type 1, Severe Combined Immunodeficiency, X Linked, Severe Combined Immunodeficiency Due to IL-7Ralpha Deficiency, Diabetes Mellitus, Permanent Neonatal, Isovaleric Acidemia, Severe Combined Immunodeficiency T-Cell Negative B-Cell Positive Due to Janus Kinase-3 Deficiency (Disorder), Jervell and Lange-Nielsen Syndrome 2, Hyperinsulinemic Hypoglycemia, Familial, 2, Diabetes Mellitus, Permanent Neonatal, With Neurologic Features, Jervell and Lange-Nielsen Syndrome 1, Lysosomal Acid Lipase Deficiency, CblF, 3-Methylcrotonyl CoA Carboxylase 1 Deficiency, 3-Methylcrotonyl CoA Carboxylase 2 Deficiency, Waardenburg Syndrome Type 2A, Methylmalonic Aciduria cblA Type, Methylmalonic Aciduria cblB Type, Methylmalonic Aciduria and Homocystinuria Type cblC, MAHCD, Methylmalonic Aciduria Due to Methylmalonyl-CoA Mutase Deficiency, Congenital Disorder of Glycosylation Type 1B, Mthfr Deficiency, Methylcobalamin Deficiency Type Cbl G (Disorder), Methylcobalamin Deficiency Type cblE, Usher Syndrome, Type 1B, N-acetylglutamate Synthase Deficiency, Ornithine Transcarbamylase Deficiency, Phenylketonurias, Waardenburg Syndrome Type 1, Congenital Hypothyroidism, Propionic Acidemia, Usher Syndrome, Type 1F, Pancreatic Agenesis 1, Hereditary Hypophosphatemic Rickets, Glycogen Storage Disease IXB, Glycogen Storage Disease IXC, MOWS, Epilepsy, Early-Onset, Vitamin B6-Dependent, Pyridoxal Phosphate-Responsive Seizures, Pituitary Hormone Deficiency, Combined, 1, Ptsd, Dihydropteridine Reductase Deficiency, Severe Combined Immunodeficiency Due to RAG1 Deficiency, Severe Combined Immunodeficiency Due to RAG2 Deficiency, Retinoblastoma, Multiple Endocrine Neoplasia Type 2B, Pseudohypoaldosteronism, Type I, Liddle Syndrome, Biotin-Responsive Basal Ganglia Disease, SCD, DIAR1, GSD1C, Acrodermatitis Enteropathica, Thyroid Dyshormonogenesis 1, Riboflavin Transporter Deficiency, Waardenburg Syndrome, Type 2E, SRD, Congenital Lipoid Adrenal Hyperplasia Due to STAR Deficiency, Barth Syndrome, Adrenocorticotropic Hormone Deficiency, Transcobalamin II Deficiency, Thyroid Dyshormonogenesis 3, Segawa Syndrome, Autosomal Recessive, Autosomal Recessive Nonsyndromic Hearing Loss, Thyroid Dyshormonogenesis 2A, Congenital Isolated Thyroid Stimulating Hormone Deficiency, Hypothyroidism Due to TSH Receptor Mutations, Usher Syndrome Type 1C, Usher Syndrome Type 1G (Diagnosis), Von Willebrand Disease, Type 3, Combined Immunodeficiency Due to ZAP70 Deficiency, Adenine Phosphoribosyltransferase Deficiency, Metachromatic Leukodystrophy, Canavan Disease, Menkes Disease, Carbonic Anhydrase VA Deficiency, Developmental and Epileptic Encephalopathy 2, 17 Alpha-Hydroxylase Deficiency, Smith-Lemli-Opitz Syndrome, Krabbe Disease, Glutathione Synthetase Deficiency, Mucopolysaccharidosis Type 7, Rett Syndrome, Molybdenum Cofactor Deficiency, Type A, Niemann-Pick Disease, Type C1, Niemann-Pick Disease Type C2, Ornithine Aminotransferase Deficiency, 3-Phosphoglycerate Dehydrogenase Deficiency, Leber Congenital Amaurosis 2, Dravet Syndrome, Mucopolysaccharidosis Type 3 A, Ornithine Translocase Deficiency, Carnitine-acylcarnitine Translocase Deficiency, Glucose Transporter Type 1 Deficiency Syndrome, Creatine Transporter Deficiency, Niemann-Pick Disease Type A, Pitt Hopkins Syndrome, Tuberous Sclerosis 1, Tuberous Sclerosis 2, Ataxia With Isolated Vitamin E Deficiency, Angelman Syndrome, Prader-Willi Syndrome, Homocystinuria, Permanent Neonatal Diabetes Mellitus, Transient Neonatal Diabetes Mellitus, Factor VII Deficiency, Glycogen Storage Disease Type IXA1, Glycogen Storage Disease, Type IXA2, Glycogen Storage Disease IC, Glycogen Storage Disease Type IB, Central Hypoventilation Syndrome With or Without Hirschsprung Disease
- Interventions
- Confirmatory Testing
- Diagnostic Test
- Lead sponsor
- RTI International
- Other
- Eligibility
- 1 Day to 31 Days
- Enrollment
- 30,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Research Triangle Park, North Carolina
- Conditions
- Ischemia and No Obstructive Coronary Artery Disease, Coronary Microvascular Dysfunction, Coronary Vasospasm, Endothelial Dysfunction, Microvascular Angina, Chest Pain With Normal Coronary Angiography
- Interventions
- Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire
- Diagnostic Test
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2032
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Stanford, California • New Haven, Connecticut + 5 more
- Conditions
- Metabolic Syndrome X, Diabetes Mellitus, Type 2
- Interventions
- topiramate
- Drug
- Lead sponsor
- Northeastern Ohio Universities College of Medicine
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 5
- States / cities
- Akron, Ohio • Canton, Ohio • Youngstown, Ohio
- Conditions
- Coronary Artery Disease, Coronary Microvascular Disease
- Interventions
- Not listed
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Microvascular Angina
- Interventions
- Ranolazine, Placebo
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Peripheral Artery Disease, Coronary Disease, Diabetes and Heart Failure, Dilated Cardiomyopathy, Heart Failure, Renal Artery Stenosis, Pulmonary Hypertension
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 2009
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Psoriasis, Metabolic Syndrome, Hyperlipidemia, Obesity, Hypertension
- Interventions
- Etanercept
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hypertension, Cardiovascular Diseases, Diabetes Mellitus, Metabolic Syndrome X
- Interventions
- Not listed
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,072 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Metabolic Syndrome x
- Interventions
- Study drugs: Metformin and fenofibrate, Study Drug: Metformin, Study Drug: fenofibrate, Metformin and Fenofibrate placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Metabolic Syndrome X, Prediabetic State
- Interventions
- Fenofibrate 145mg PO QD, Pioglitazone 45 mg PO QD
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Metabolic Syndrome X, Inflammation
- Interventions
- High Dietary Flavonoids, Low Dietary Flavonoids
- Other
- Lead sponsor
- Utah State University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Logan, Utah
- Conditions
- Non-obstructive Coronary Disease, Acute or Chronic Coronary Artery Disease
- Interventions
- Patients with intermediate coronary artery stenosis with clinically indicated FFR assessment., Microvascular assessment
- Procedure
- Lead sponsor
- AngioInsight
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 620 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 9
- States / cities
- Palo Alto, California • Washington D.C., District of Columbia • Minneapolis, Minnesota + 4 more
- Conditions
- Metabolic Syndrome X
- Interventions
- NOS Inhibition, ET-1 Inhibition, NOS Inhibition Placebo, 3 Tesla MRI, Intravenous Catheter, Oral Glucose Tolerance Test, ET-1 Inhibition Placebo
- Drug · Device · Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Cardiovascular Diseases, Heart Diseases, Obesity, Hyperlipidemia, Insulin Resistance, Metabolic Syndrome X
- Interventions
- Resistance Training, Aerobic Exercise, Combo, Continued Sedentary lifestyle
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 261 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Angina Pectoris, Microvascular Angina, Vasospastic Angina, Myocardial Bridge of Coronary Artery
- Interventions
- Amlodipine, Nebivolol, Placebo
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Palo Alto, California